Zoetis Inc. (NYSE:ZTS) Shares Sold by Stokes Family Office LLC

Stokes Family Office LLC lessened its holdings in Zoetis Inc. (NYSE:ZTS) by 29.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,734 shares of the company’s stock after selling 1,547 shares during the quarter. Stokes Family Office LLC’s holdings in Zoetis were worth $737,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Vaughan Nelson Investment Management L.P. acquired a new stake in shares of Zoetis during the 3rd quarter worth approximately $176,219,000. Alphinity Investment Management Pty Ltd grew its stake in shares of Zoetis by 214.7% during the 4th quarter. Alphinity Investment Management Pty Ltd now owns 824,148 shares of the company’s stock worth $162,662,000 after purchasing an additional 562,259 shares during the period. International Assets Investment Management LLC grew its stake in shares of Zoetis by 27,671.0% during the 4th quarter. International Assets Investment Management LLC now owns 479,328 shares of the company’s stock worth $94,605,000 after purchasing an additional 477,602 shares during the period. Envestnet Asset Management Inc. grew its stake in shares of Zoetis by 34.8% during the 3rd quarter. Envestnet Asset Management Inc. now owns 1,562,044 shares of the company’s stock worth $271,764,000 after purchasing an additional 403,164 shares during the period. Finally, Natixis Advisors L.P. grew its stake in shares of Zoetis by 53.9% during the 3rd quarter. Natixis Advisors L.P. now owns 941,219 shares of the company’s stock worth $163,753,000 after purchasing an additional 329,543 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $151.17, for a total transaction of $139,529.91. Following the transaction, the executive vice president now owns 14,800 shares in the company, valued at approximately $2,237,316. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 2,209 shares of company stock worth $371,293 in the last quarter. Company insiders own 0.16% of the company’s stock.

Zoetis Price Performance

ZTS stock traded down $0.16 during midday trading on Friday, reaching $167.07. The stock had a trading volume of 3,007,125 shares, compared to its average volume of 4,607,073. The company’s fifty day simple moving average is $169.48 and its 200 day simple moving average is $178.89. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32. The company has a market cap of $76.41 billion, a price-to-earnings ratio of 32.19, a price-to-earnings-growth ratio of 2.62 and a beta of 0.86. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, May 2nd. The company reported $1.38 earnings per share for the quarter, beating analysts’ consensus estimates of $1.34 by $0.04. The company had revenue of $2.19 billion for the quarter, compared to analyst estimates of $2.14 billion. Zoetis had a return on equity of 50.74% and a net margin of 27.38%. The firm’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same quarter last year, the firm posted $1.31 EPS. As a group, sell-side analysts predict that Zoetis Inc. will post 5.78 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be issued a dividend of $0.432 per share. The ex-dividend date is Thursday, April 18th. This represents a $1.73 annualized dividend and a dividend yield of 1.03%. Zoetis’s dividend payout ratio is presently 33.33%.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on ZTS shares. StockNews.com cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. The Goldman Sachs Group increased their target price on Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a research report on Wednesday, January 17th. Stifel Nicolaus decreased their target price on Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday. Piper Sandler reiterated an “overweight” rating and set a $195.00 target price (down previously from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. Finally, Barclays decreased their target price on Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 23rd. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Zoetis has an average rating of “Buy” and a consensus target price of $216.13.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.